- Open Access
Anthrax immune globulin improves hemodynamics and survival during B. anthracis toxin-induced shock in canines receiving titrated fluid and vasopressor support
© The Author(s). 2017
Received: 12 April 2017
Accepted: 22 September 2017
Published: 23 October 2017
Although anthrax immune globulin (AIG) improved survival in antibiotic-treated Bacillus anthracis-challenged animal models, whether it adds to the benefit of conventional hemodynamic support for B. anthracis toxin-associated shock is unknown.
We therefore tested AIG in sedated, mechanically ventilated canines challenged with 24-h B. anthracis lethal and edema toxin infusions and supported for 96 h with a previously demonstrated protective regimen of titrated normal saline and norepinephrine.
Compared to controls, proportional survival (%) was increased with AIG treatment started 4 h before (33 vs. 100%, n = 6 each) or 2 h (17 vs. 86%, n = 6 and 7 respectively) or 5 h (0 vs. 67%, n = 3 each) after the start of toxin (p ≤ 0.05) and overall [3 survivors of 15 controls (20%) vs. 14 of 16 AIG animals (88%); p = 0.006]. Averaged across treatment times, AIG increased blood pressure at 48 h and decreased norepinephrine requirements at 72 h (p ≤ 0.02), increased left ventricular ejection fraction at 48 and 72 h (p ≤ 0.02), and increased urine output and decreased net fluid balance at 72 and 96 h (p ≤ 0.04). AIG also reduced acidosis and renal and hepatic injury markers between 24 and 96 h.
These findings further support AIG’s potential benefit for patients with B. anthracis infection and developing toxin-associated shock.
Bacillus anthracis (anthrax) lethal and edema toxins (LT and ET respectively) are strongly linked to the pathogenesis of shock during anthrax infection. The Centers for Disease Control and Prevention (CDC) Guidelines now recommend that, besides antibiotic and cardiopulmonary support, patients with systemic anthrax infection receive an anti-toxin agent [1–7]. At this time, anthrax immune globulin (AIG; Emergent BioSolutions, Gaithersburg, MD) is the only anti-toxin agent with US Food and Drug Administration (FDA) approval that has also been administered to patients with anthrax infection [7, 8]. Anthrax immune globulin is a polyclonal antibody directed at the protective antigen (PA) component of the toxins which was originally produced by Cangene Corp. until this company was acquired by Emergent BioSolutions [9, 10].
Due to the infrequency of invasive anthrax infection in humans, AIG received approval based on studies showing it increased survival in an anthrax-challenged and antibiotic-treated rabbit model . However, since these studies were conducted at high biosafety levels limiting animal contact, they did not determine whether AIG would improve outcome when combined with the titrated hemodynamic support patients with infection- and toxin-related shock receive. Experiences with AIG during systemic anthrax infection in 3 isolated inhalational cases and 15 cases from an outbreak due to contaminated heroin injection have also not answered this question [12–15]. In fact, in this outbreak, AIG did not improve outcome in the 15 patients receiving treatment compared to 28 non-recipients, although recipients were sicker . Determining whether AIG adds to the beneficial effects of hemodynamic support would provide additional insight and confidence as to its clinical efficacy.
We previously developed a 96-h sedated, instrumented, and mechanically ventilated canine model of anthrax toxin-associated shock in which LT and ET were infused over 24 h to simulate release during infection . In this model, support with fluids and vasopressors titrated with pulmonary and systemic arterial catheters improved hemodynamics and survival during the development of toxin-associated shock . Therefore, to further explore AIG’s efficacy, here we compared its effects to placebo when administered earlier or later in canines challenged with 24-h infusions of LT and ET and treated with this protective regimen of hemodynamic support.
Toxin and treatments
Lethal and edema toxin infusions were prepared and administered as described previously . AIG was supplied by the CDC (lot number 10602912, Cangene Corporation, Winnipeg, Canada) at a standard concentration of 2.18 mg/mL in 50-mL vials. AIG animals received the manufacturer-recommended pediatric dose (1.5 vials for a 10–20-kg patient) . Control animals received an equivalent dose of IVIG (Gamunex, Grifols Therapeutics, Clayton, NC). To minimize hypersensitivity reactions to the human protein, AIG and IVIG were administered in gradually escalating doses as outlined in Additional file 2: Table S2. The animals received the initial 50% of their treatment dose over 4 h before and the final 50% over 2 h after the designated treatment times (Fig. 1). The animals also received diphenhydramine (1 mg/kg IV) every 6 h for three doses and famotidine (1 mg/kg) every 12 h starting with the AIG and IVIG treatments.
Prior to AIG or IVIG, animals received up to three boluses (20 cm3/kg) of saline until a pulmonary capillary wedge pressure (PCWP) of at least 10 mmHg was achieved. Thereafter, animals with a PCWP < 10 mmHg after routine measurements were treated with additional 20 mL/kg normal saline boluses (Fig. 1). Any time the mean arterial blood pressure (MAP) was < 80 mmHg for > 5 min, a norepinephrine infusion was started at 0.2 μg/kg/min and increased stepwise to a maximum of 2 μg/kg/min if needed. Norepinephrine was similarly decreased stepwise if MAP was > 110 mmHg. Administered norepinephrine amounts were recorded every 2 h for each animal. Ventilator management, temperature control, and sedation with midazolam, fentanyl, and medetomidine were managed uniformly for all animals based on previously reported protocols . Additional animal care included pharmacologic prophylaxis for gastrointestinal stress ulcers (famotidine), deep vein thrombosis (subcutaneous heparin), and ceftriaxone to prevent catheter-related infection . Animal technicians administering support to animals were blinded throughout the study to treatment assignments (i.e., AIG vs. IVIG).
Survival times were plotted in Kaplan-Meyer curves and analyzed using stratified log-rank test and stratified Cox proportional hazard model. For all other variables, changes from baseline values at each subsequent time point were analyzed. To evaluate shock reversal, we standardized MAP and NE using Z-scores and then calculated a Shock Index score based on the difference of the MAP Z-score and NE Z-score. Increased or decreased scores represent improved or worsened hemodynamic function respectfully. Linear mixed models were used to account for the pairing of animals within each cycle. Standard residual diagnostics were used to check model assumptions. Logarithm-transformation was used when necessary. SAS version 9.3 (Cary, NC) was used for all analyses. Data is presented from the completion of toxin challenge at 24 h to the end of the study at 96 h. All p values are two-tailed and considered significant if p ≤ 0.05. One animal in the T2 control group received D5W and not IVIG as placebo and was not included in the analysis.
Hemodynamic and pulmonary function
At baseline before toxin infusion, only 1 out of 40 parameters had a significant p value comparing control and AIG and this was no more than what would be expected by chance alone (Additional file 8: Table S8). Data is therefore shown as serial mean (± SEM) changes from baseline for all parameters except fluid and urine amounts, which are shown as hourly amounts averaged for each preceding 24-h period (see below).
Renal, hepatic, and hematologic data
In canines challenged with 24-h LT and ET infusions and provided a protective regimen of titrated hemodynamic support similar to what is applied clinically for shock, AIG treatment improved survival. This protection was evident even when the AIG dose was administered from 5 to 11 h after the start of toxin. These findings add to data from an antibiotic-treated, anthrax-challenged animal model, suggesting that AIG will have benefit when administered in patients with systemic infection and developing toxin-related shock and organ injury .
Based on evolving concepts regarding LT and ETs’ pathogenic effects, AIG may have improved survival several ways. First, both LT and ET appear to cause endothelial injury, which in vivo could produce extravasation and loss of intravascular volume [5, 20–22]. This fluid movement can produce either systemic hypotension with secondary reductions in organ perfusion or direct organ injury if tissue edema interferes with oxygen and nutrient uptake [23–27]. Although control and AIG animals received similar larger supporting fluid volumes over the first 24 h, subsequent urine output was increased and net fluid balance decreased with AIG, suggesting that treatment prevented extravasation of fluid. Consistent with this, total protein, albumin, and platelets were decreased early or later with AIG, suggesting that retention of intravascular volume caused hemodilution. Retained intravascular volume with AIG may have helped improve blood pressure and reduced vasopressor needs. Second, studies now show that ET reduces arterial contractile force and response to catecholamines, resulting in increased arterial relaxation [28, 29]. Lethal toxin may also alter vascular smooth muscle function . These effects in vivo would cause arterial dilation and hypotension. Thus, AIG may have helped maintain arterial contractile function and its response to endogenous catecholamines and norepinephrine treatment, effects consistent with the increased blood pressure and reduced norepinephrine requirements in treated animals. Third, LT has been associated in several animal models including this canine one, with left ventricular systolic dysfunction [6, 30–32]. It is therefore noteworthy that AIG produced increased left ventricular ejection fraction and stroke volume from 48 to 96 h. Although this effect may have been related to improved preload due to retention of intravascular volume, PCWP was actually reduced with AIG.
Overall, whether related to improved intravascular volume or arterial contractile or myocardial systolic function, increased survival with AIG likely resulted from increased organ perfusion and reduced organ injury. Treated animals had decreased lactate and improved lung, kidney, and liver function as reflected by improved oxygenation and reductions in creatinine, BUN, liver enzymes, and clotting times.
At this time, besides AIG, Raxibacumab (GlaxoSmithKline, Rockville, MD) is the other anti-toxin agent that has received FDA approval for use during anthrax infection and been included in the SNS. Raxibacumab is a humanized chimpanzee monoclonal antibody (mAb) directed against PA [4, 33–35]. This agent also received FDA approval based on a study showing it improved survival in anthrax-challenged and antibiotic-treated rabbits . Although Raxibacumab has not been administered clinically, we previously tested it in our toxin-challenged canine model [16, 37]. All animals in that prior study received the same titrated hemodynamic and ventilatory support as the animals in the present study received. Raxibacumab infused over 30 min increased survival when administered at the time of or at 9 h after the start of toxin challenge. It also increased blood pressure and decreased norepinephrine requirements and improved urine output, fluid clearance, and liver function. Thus, based on data from both bacteria-challenged models treated with antibiotics and our toxin-challenged canine model treated with titrated cardiopulmonary support, AIG and Raxibacumab appear to have comparable beneficial effects. However, there are potential advantages when comparing polyclonal to monoclonal preparations . A polyclonal preparation is directed at multiple epitopes and might be less likely to lose effectiveness in the setting of a bacterial strain engineered to produce a toxin resistant to available monoclonal preparations. Also, a polyclonal preparation can also elicit several different effector cell functions which may improve ultimate bacterial clearance. Although mixes of monoclonal antibodies can be prepared to address this problem, that can be a costly solution. To fully determine these agents’ similarity will require an analysis of their effects when applied in patients with similarly severe bacterial infection. A humanized mouse anti-PA mAb, ETI-204, has also received FDA approval based on studies in anthrax-challenged and antibiotic-treated animal models but has not been tested in this toxin-challenged canine model [39–41].
Prior measurements in this canine model suggest that the toxin challenges produced circulating toxin levels comparable to ones with anthrax infection. Previously, for canines challenged with 24-h LT infusions at doses similar to the ones used here, PA levels (mean ± SEM) at toxin infusion completion were 34 ± 3 ng/mL. This level was within the range of ones measured in cynomolgus monkeys challenged with LD200 doses of anthrax spores, in which PA levels increased from 1.3 ± 2.3 ng/mL at 30 h to 178.3 ± 37.4 ng/mL at 72 h . The level of 34 ± 3 ng/mL was also similar to one of 68.7 ng/mL reported for a patient with inhalational anthrax infection .
The latest treatment tested in this study that was started and completed 5 and 11 h, respectively, following the initiation of toxin challenge had beneficial effects comparable to earlier treatment times. However, even this treatment is much earlier than will likely occur in patients presenting during an actual outbreak of infection. In the 2009 outbreak of soft tissue infection, the median time (IQR) from the onset of symptoms to hospital presentation was 2 days [1, 5], and administration of AIG occurred hours after that related to the need to confirm the presence B. anthracis . Administration of AIG in isolated cases of inhalational disease have also occurred well after the onset of symptoms. Whether AIG or other antibody preparations will prove beneficial with these types of delay is unclear. Two studies in rabbits did show that initiation of either AIG or Raxibacumab along with antibiotics up to 96 h after challenge with live B. anthracis resulted in trends towards improved survival compared to antibiotics alone [19, 33].
Due to the sensitivity of canines to the human protein in AIG, treatment had to be administered in escalating doses over a 6-h and 22-min period. This regimen resulted in half of each effective dose being given prior to and the other half following the designated treatment time point. However, this regimen was similar to the one employed during AIG administration in the outbreak of anthrax soft tissue infection in the UK . Notably in the present study, the T2 and T5 groups began to receive AIG treatment as animals were beginning to require fluid and vasopressor support for developing hypotension.
A smaller number of animals were studied with AIG at the T9-designated treatment time point than at earlier ones. However, AIG treatment at this later time point did have a significant effect on survival that was similar to that of earlier treatment, and the use of additional limited animal resources for study with the T5 treatment was not justified.
Findings in this canine model demonstrate that AIG treatment can improve survival when combined with conventional hemodynamic support in anthrax toxin-challenged animals. Prior studies by others have shown that AIG can improve survival when combined with antibiotic therapy in anthrax-challenged animal models. Together these findings provide support for the use of AIG in patients with systemic anthrax infection. Other similar findings would also support the use of Raxibacumab. However, until these anti-toxin agents are investigated along with both antibiotic and cardiopulmonary support either in anthrax-challenged animal models or in infected patients, their actual effectiveness will be unknown.
This work was supported by funding from the Clinical Center and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health and from the FDA Medical Countermeasures Division. Anthrax immune globulin was provided by Dr. William Bowers of the CDC.
Portions of this research were presented as an abstract at the 2014 International Conference of the American Thoracic Society, and a portion of it has been submitted as an abstract to the 2017 International Conference of the American Thoracic Society.
DAS helped perform experiments and drafted and edited the manuscript. XC, DJ, KER, YL, SBS, and YF all helped perform experiments and collect data and helped in interpretation of the data and editing of the manuscript. JS performed all statistical analyses for this study. MM and SL contributed toxin for use in the experiment and also helped review and edit the manuscript. PQE helped design the experiments, interpreted the data, drafted the manuscript, and edited the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The National Institutes of Health Clinical Center Animal Care and Use Committee approved this study.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ (2011) Anthrax infection. Am J Respir Crit Care Med 184:1333–1341View ArticlePubMedPubMed CentralGoogle Scholar
- Pezard C, Berche P, Mock M (1991) Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun 59:3472–3477PubMedPubMed CentralGoogle Scholar
- Cui X, Li Y, Li X, Laird MW, Subramanian M, Moayeri M, Leppla SH, Fitz Y, Su J, Sherer K, Eichacker PQ (2007) Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis 195:572–580View ArticlePubMedGoogle Scholar
- Sweeney DA, Cui X, Solomon SB, Vitberg DA, Migone TS, Scher D, Danner RL, Natanson C, Subramanian GM, Eichacker PQ (2010) Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J Infect Dis 202:1885–1896View ArticlePubMedPubMed CentralGoogle Scholar
- Warfel JM, Steele AD, D’Agnillo F (2005) Anthrax lethal toxin induces endothelial barrier dysfunction. Am J Pathol 166:1871–1881View ArticlePubMedPubMed CentralGoogle Scholar
- Watson LE, Mock J, Lal H, Lu G, Bourdeau RW, Tang WJ, Leppla SH, Dostal DE, Frankel AE (2007) Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. Front Biosci 12:4670–4675View ArticlePubMedGoogle Scholar
- Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney-Delman D (2015) Clinical framework and medical countermeasure use during an anthrax mass-casualty incident. MMWR Recomm Rep 64:1–22View ArticlePubMedGoogle Scholar
- Huang E, Pillai SK, Bower WA, Hendricks KA, Guarnizo JT, Hoyle JD, Gorman SE, Boyer AE, Quinn CP, Meaney-Delman D (2015) Antitoxin treatment of inhalation anthrax: a systematic review. Health Secur 13:365–377View ArticlePubMedPubMed CentralGoogle Scholar
- Mytle N, Hopkins RJ, Malkevich NV, Basu S, Meister GT, Sanford DC, Comer JE, Van Zandt KE, Al-Ibrahim M, Kramer WG, Howard C, Daczkowski N, Chakrabarti AC, Ionin B, Nabors GS, Skiadopoulos MH (2013) Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother 57:5684–5692View ArticlePubMedPubMed CentralGoogle Scholar
- Hopkins RJ, Kalsi G, Montalvo-Lugo VM, Sharma M, Wu Y, Muse DD, Sheldon EA, Hampel FC, Lemiale L (2016) Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults. Vaccine 34:2096–2105View ArticlePubMedPubMed CentralGoogle Scholar
- Fisher RW (2015) Summary basis for regulatory action—Anthrasil. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM443728.pdf. Accessed 10 Jan 2017
- Cui X, Nolen LD, Sun J, Booth M, Donaldson L, Quinn CP, Boyer AE, Hendricks K, Shadomy S, Bothma P, Judd O, McConnell P, Bower WA, Eichacker PQ (2017) Analysis of anthrax immune globulin intravenous with antimicrobial treatment in injection drug users, Scotland, 2009-2010. Emerg Infect Dis 23:56–65View ArticlePubMedPubMed CentralGoogle Scholar
- Walsh JJ, Pesik N, Quinn CP, Urdaneta V, Dykewicz CA, Boyer AE, Guarner J, Wilkins P, Norville KJ, Barr JR, Zaki SR, Patel JB, Reagan SP, Pirkle JL, Treadwell TA, Messonnier NR, Rotz LD, Meyer RF, Stephens DS (2007) A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 44:968–971View ArticlePubMedGoogle Scholar
- Griffith J, Blaney D, Shadomy S, Lehman M, Pesik N, Tostenson S, Delaney L, Tiller R, DeVries A, Gomez T, Sullivan M, Blackmore C, Stanek D, Lynfield R (2014) Investigation of inhalation anthrax case, United States. Emerg Infect Dis 20:280–283View ArticlePubMedPubMed CentralGoogle Scholar
- Centers for Disease Control and Prevention (2006) Inhalation anthrax associated with dried animal hides—Pennsylvania and New York City, 2006. MMWR Morb Mortal Wkly Rep 55:280–282Google Scholar
- Barochia AV, Cui X, Sun J, Li Y, Solomon SB, Migone TS, Subramanian GM, Bolmer SD, Eichacker PQ (2012) Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines. J Infect Dis 205:818–829View ArticlePubMedPubMed CentralGoogle Scholar
- Package insert and patient information—ANTHRASIL (2015). Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM439812.pdf. Accessed 10 Jan 2017
- Minneci PC, Deans KJ, Hansen B, Parent C, Romines C, Gonzales DA, Ying SX, Munson P, Suffredini AF, Feng J, Solomon MA, Banks SM, Kern SJ, Danner RL, Eichacker PQ, Natanson C, Solomon SB (2007) A canine model of septic shock: balancing animal welfare and scientific relevance. Am J Physiol Heart Circ Physiol 293:H2487–H2500View ArticlePubMedGoogle Scholar
- Kammanadiminti S, Patnaikuni RK, Comer J, Meister G, Sinclair C, Kodihalli S (2014) Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax. PLoS One 9:e106393View ArticlePubMedPubMed CentralGoogle Scholar
- Guichard A, McGillivray SM, Cruz-Moreno B, van Sorge NM, Nizet V, Bier E (2010) Anthrax toxins cooperatively inhibit endocytic recycling by the Rab11/Sec15 exocyst. Nature 467:854–858View ArticlePubMedGoogle Scholar
- Warfel JM, D’Agnillo F (2011) Anthrax lethal toxin-mediated disruption of endothelial VE-cadherin is attenuated by inhibition of the Rho-associated kinase pathway. Toxins (Basel) 3:1278–1293View ArticleGoogle Scholar
- D’Agnillo F, Williams MC, Moayeri M, Warfel JM (2013) Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions. PLoS One 8:e62576View ArticlePubMedPubMed CentralGoogle Scholar
- Hicks CW, Cui X, Sweeney DA, Li Y, Barochia A, Eichacker PQ (2011) The potential contributions of lethal and edema toxins to the pathogenesis of anthrax associated shock. Toxins (Basel) 3:1185–1202View ArticleGoogle Scholar
- Remy KE, Qiu P, Li Y, Cui X, Eichacker PQ (2013) B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components. BMC Med 11:217View ArticlePubMedPubMed CentralGoogle Scholar
- Coggeshall KM, Lupu F, Ballard J, Metcalf JP, James JA, Farris D, Kurosawa S (2013) The sepsis model: an emerging hypothesis for the lethality of inhalation anthrax. J Cell Mol Med 17:914–920View ArticlePubMedPubMed CentralGoogle Scholar
- Golden HB, Watson LE, Lal H, Verma SK, Foster DM, Kuo SR, Sharma A, Frankel A, Dostal DE (2009) Anthrax toxin: pathologic effects on the cardiovascular system. Front Biosci (Landmark Ed) 14:2335–2357View ArticleGoogle Scholar
- Goldman DL, Casadevall A (2008) Anthrax-associated shock. Front Biosci 13:4009–4014PubMedGoogle Scholar
- Li Y, Cui X, Solomon SB, Remy K, Fitz Y, Eichacker PQ (2013) B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model. Am J Physiol Heart Circ Physiol 305:H238–H250View ArticlePubMedPubMed CentralGoogle Scholar
- Li Y, Cui X, Xu W, Ohanjanian L, Sampath-Kumar H, Suffredini D, Moayeri M, Leppla S, Fitz Y, Eichacker PQ (2016) Nitric oxide production contributes to Bacillus anthracis edema toxin-associated arterial hypotension and lethality: ex vivo and in vivo studies in the rat. Am J Physiol Heart Circ Physiol 311:H781–H793View ArticlePubMedPubMed CentralGoogle Scholar
- Liu S, Zhang Y, Moayeri M, Liu J, Crown D, Fattah RJ, Wein AN, Yu ZX, Finkel T, Leppla SH (2013) Key tissue targets responsible for anthrax-toxin-induced lethality. Nature 501:63–68View ArticlePubMedPubMed CentralGoogle Scholar
- Watson LE, Kuo SR, Katki K, Dang T, Park SK, Dostal DE, Tang WJ, Leppla SH, Frankel AE (2007) Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS One 2:e466View ArticlePubMedPubMed CentralGoogle Scholar
- Suffredini DA, Sampath-Kumar H, Li Y, Ohanjanian L, Remy KE, Cui X, Eichacker PQ (2015) Does Bacillus anthracis lethal toxin directly depress myocardial function? A review of clinical cases and preclinical studies. Toxins (Basel) 7:5417–5434View ArticleGoogle Scholar
- Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD (2009) Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361:135–144View ArticlePubMedGoogle Scholar
- Kummerfeldt CE (2014) Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist 7:101–109View ArticlePubMedPubMed CentralGoogle Scholar
- Migone TS, Bolmer S, Zhong J, Corey A, Vasconcelos D, Buccellato M, Meister G (2015) Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax. Antimicrob Agents Chemother 59:1145–1151View ArticlePubMedPubMed CentralGoogle Scholar
- Tsai CW, Morris S (2015) Approval of Raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration “Animal Rule”. Front Microbiol 6:1320View ArticlePubMedPubMed CentralGoogle Scholar
- Remy KE, Cui X, Li Y, Sun J, Solomon SB, Fitz Y, Barochia AV, Al-Hamad M, Moayeri M, Leppla SH, Eichacker PQ (2015) Raxibacumab augments hemodynamic support and improves outcomes during shock with B. anthracis edema toxin alone or together with lethal toxin in canines. Intensive Care Med Exp 3:9View ArticlePubMedPubMed CentralGoogle Scholar
- Lipman NS, Jackson LR, Trudel LJ (2005) Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications and information resources. ILAR J 46:258–268View ArticlePubMedGoogle Scholar
- Biron B, Beck K, Dyer D, Mattix M, Twenhafel N, Nalca A (2015) Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother 59:2206–2214View ArticlePubMedPubMed CentralGoogle Scholar
- Greig SL (2016) Obiltoxaximab: first global approval. Drugs 76:823–830View ArticlePubMedGoogle Scholar
- Yamamoto BJ, Shadiack AM, Carpenter S, Sanford D, Henning LN, Gonzales N, O’Connor E, Casey LS, Serbina NV (2016) Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre- and postexposure prophylaxis in animal models of inhalational anthrax. Antimicrob Agents Chemother 60:5796–5805View ArticlePubMedPubMed CentralGoogle Scholar
- Stoddard RA, Quinn CP, Schiffer JM, Boyer AE, Goldstein J, Bagarozzi DA, Soroka SD, Dauphin LA, Hoffmaster AR (2014) Detection of anthrax protective antigen (PA) using europium labeled anti-PA monoclonal antibody and time-resolved fluorescence. J Immunol Methods 408:78–88View ArticlePubMedPubMed CentralGoogle Scholar